AF
FDMT icon

Amalgamated Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Amalgamated Financial’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$53K Buy
+3,495
New +$54.9K ﹤0.01% 2402

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Amalgamated Financial's FDMT Position: Q1 2022 in Review

Amalgamated Financial opened a new position in 4D Molecular Therapeutics (FDMT) in Q1 2022: 3,495 shares worth $53K. The stake represents ﹤0.01% of the portfolio and ranks #2402 among its holdings.

80 funds tracked by Wall St. Rank hold FDMT as of Q1 2022.

  • Amalgamated Financial held 3,495 shares of 4D Molecular Therapeutics worth $53K as of Q1 2022.
  • 4D Molecular Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • 4D Molecular Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2402 holding.
  • 80 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.